A Study of LY3209590 in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of LY3209590 when given by injection
under the skin to participants with type 2 diabetes. It will also investigate how the body
processes the study drug and the effect of the study drug on blood sugar levels. Information
about any side effects will be documented.
This study will last approximately 17 weeks, not including screening. Screening is required
within 4 weeks prior to the start of the study.